176 related articles for article (PubMed ID: 24618809)
1. Preclinical assessment of carboplatin treatment efficacy in lung cancer by 18F-ICMT-11-positron emission tomography.
Witney TH; Fortt R; Aboagye EO
PLoS One; 2014; 9(3):e91694. PubMed ID: 24618809
[TBL] [Abstract][Full Text] [Related]
2. Clinical translation of [
Dubash SR; Merchant S; Heinzmann K; Mauri F; Lavdas I; Inglese M; Kozlowski K; Rama N; Masrour N; Steel JF; Thornton A; Lim AK; Lewanski C; Cleator S; Coombes RC; Kenny L; Aboagye EO
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2285-2299. PubMed ID: 30259091
[TBL] [Abstract][Full Text] [Related]
3. Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging.
Nguyen QD; Lavdas I; Gubbins J; Smith G; Fortt R; Carroll LS; Graham MA; Aboagye EO
Clin Cancer Res; 2013 Jul; 19(14):3914-24. PubMed ID: 23729364
[TBL] [Abstract][Full Text] [Related]
4. Depicting Changes in Tumor Biology in Response to Cetuximab Monotherapy or Combination Therapy by Apoptosis and Proliferation Imaging Using
Heinzmann K; Nguyen QD; Honess D; Smith DM; Stribbling S; Brickute D; Barnes C; Griffiths J; Aboagye E
J Nucl Med; 2018 Oct; 59(10):1558-1565. PubMed ID: 29794225
[TBL] [Abstract][Full Text] [Related]
5. 18F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry.
Challapalli A; Kenny LM; Hallett WA; Kozlowski K; Tomasi G; Gudi M; Al-Nahhas A; Coombes RC; Aboagye EO
J Nucl Med; 2013 Sep; 54(9):1551-6. PubMed ID: 23949910
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide.
Nguyen QD; Smith G; Glaser M; Perumal M; Arstad E; Aboagye EO
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16375-80. PubMed ID: 19805307
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of apoptosis imaging biomarkers in a genetic model of cell death.
Vassileva V; Stribbling SM; Barnes C; Carroll L; Braga M; Abrahams J; Heinzmann K; Haegeman C; MacFarlane M; Simpson KL; Dive C; Honeychurch J; Illidge TM; Aboagye EO
EJNMMI Res; 2019 Feb; 9(1):18. PubMed ID: 30783791
[TBL] [Abstract][Full Text] [Related]
8. Imaging caspase-3 activation as a marker of apoptosis-targeted treatment response in cancer.
Chen DL; Engle JT; Griffin EA; Miller JP; Chu W; Zhou D; Mach RH
Mol Imaging Biol; 2015 Jun; 17(3):384-93. PubMed ID: 25344147
[TBL] [Abstract][Full Text] [Related]
9. Imaging apoptosis with positron emission tomography: 'bench to bedside' development of the caspase-3/7 specific radiotracer [(18)F]ICMT-11.
Nguyen QD; Challapalli A; Smith G; Fortt R; Aboagye EO
Eur J Cancer; 2012 Mar; 48(4):432-40. PubMed ID: 22226480
[TBL] [Abstract][Full Text] [Related]
10. Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
Thézé B; Bernards N; Beynel A; Bouet S; Kuhnast B; Buvat I; Tavitian B; Boisgard R
BMC Cancer; 2015 Jul; 15():534. PubMed ID: 26198000
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of [
Rapic S; Vangestel C; Elvas F; Verhaeghe J; den Wyngaert TV; Wyffels L; Pauwels P; Staelens S; Stroobants S
Mol Imaging Biol; 2017 Aug; 19(4):560-569. PubMed ID: 28050749
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment.
Witney TH; Hoehne A; Reeves RE; Ilovich O; Namavari M; Shen B; Chin FT; Rao J; Gambhir SS
Clin Cancer Res; 2015 Sep; 21(17):3896-905. PubMed ID: 25972517
[TBL] [Abstract][Full Text] [Related]
13. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
[TBL] [Abstract][Full Text] [Related]
14. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
[TBL] [Abstract][Full Text] [Related]
15. Rational design of caspase-responsive smart molecular probe for positron emission tomography imaging of drug-induced apoptosis.
Qiu L; Wang W; Li K; Peng Y; Lv G; Liu Q; Gao F; Seimbille Y; Xie M; Lin J
Theranostics; 2019; 9(23):6962-6975. PubMed ID: 31660080
[No Abstract] [Full Text] [Related]
16. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
Dai D; Li XF; Wang J; Liu JJ; Zhu YJ; Zhang Y; Wang Q; Xu WG
Int J Cancer; 2016 Feb; 138(4):1003-12. PubMed ID: 26334931
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung Cancer.
Schelhaas S; Held A; Wachsmuth L; Hermann S; Honess DJ; Heinzmann K; Smith DM; Griffiths JR; Faber C; Jacobs AH
Cancer Res; 2016 Dec; 76(24):7096-7105. PubMed ID: 27784748
[TBL] [Abstract][Full Text] [Related]
18. A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers.
Simpson KL; Cawthorne C; Zhou C; Hodgkinson CL; Walker MJ; Trapani F; Kadirvel M; Brown G; Dawson MJ; MacFarlane M; Williams KJ; Whetton AD; Dive C
Cell Death Dis; 2013 May; 4(5):e613. PubMed ID: 23640455
[TBL] [Abstract][Full Text] [Related]
19. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
20. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.
Maynard J; Ricketts SA; Gendrin C; Dudley P; Davies BR
Mol Imaging Biol; 2013 Aug; 15(4):476-85. PubMed ID: 23344784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
